NCT07134023

Brief Summary

Background: Endometriosis is a chronic gynecological condition characterized by the ectopic presence of endometrial tissue outside the uterine cavity. It affects approximately 2 to 10% of women of reproductive age and up to 50% of women with chronic pelvic pain. In France, between 1.5 and 2.5 million women are estimated to be affected. Endometriosis significantly impairs quality of life, with consequences on cognitive, behavioral, sexual, and emotional well-being, and has substantial socio-economic impact. Rationale: Current medical and surgical treatments primarily aim to reduce pain and preserve fertility but show limited effectiveness and are often discontinued due to adverse effects. Many women resort to self-management strategies, which may pose risks if not properly supervised. A multidisciplinary and integrative approach is essential to address the complex and multifactorial symptoms of endometriosis. Therapeutic patient education (TPE) is a recommended strategy that can empower patients in the management of chronic conditions, yet remains underdeveloped in endometriosis care pathways. Objective: This study aims to evaluate the effectiveness of a multidisciplinary educational program combined with nurse-led telephone follow-up on the quality of life of patients with endometriosis. Methods: The intervention will consist of a series of workshops led by various healthcare professionals (medical and paramedical), alongside regular nurse-led telephone follow-up. This approach intends to provide continuous support, assess patients' evolving needs, and facilitate access to supportive care services, particularly within regional endometriosis networks (ENDAURA and ENDOSUD). Expected Outcomes: The study will assess whether this intervention improves quality of life among women with endometriosis. It also aims to provide evidence for the scalability and transferability of such a program at a national level, in alignment with current public health priorities.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
260

participants targeted

Target at P75+ for not_applicable

Timeline
32mo left

Started Dec 2025

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Dec 2025Jan 2029

First Submitted

Initial submission to the registry

August 7, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

August 21, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

December 17, 2025

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2029

Last Updated

December 22, 2025

Status Verified

December 1, 2025

Enrollment Period

3 years

First QC Date

August 7, 2025

Last Update Submit

December 19, 2025

Conditions

Keywords

EndometriosisQuality of lifeMultidisciplinaryNurse follow-up

Outcome Measures

Primary Outcomes (1)

  • Endometriosis Health Profile-30 (EHP-30)

    Change in quality of life, measured by the Endometriosis Health Profile-30 (EHP-30) score, from baseline (T0) to 12 months (M12), in the experimental group receiving a multidisciplinary educational program with nurse-led telephone follow-up compared with the control group receiving standard care.

    baseline (T0) to 6 months and 12 months (M12)

Secondary Outcomes (9)

  • Anxiety

    baseline (T0), 6 months (M6), and 12 months (M12).

  • Score of the the brief pain inventory

    baseline (T0), 6 months (M6), and 12 months (M12).

  • dyspareunia and dysmenorrhea

    baseline (T0), 6 months (M6), and 12 months (M12)

  • Female Sexual Function

    baseline (T0), 6 months (M6), and 12 months (M12).

  • Sleep

    baseline (T0), 6 months (M6), and 12 months (M12).

  • +4 more secondary outcomes

Study Arms (2)

The experimental group will participate in a therapeutic education and nursing support

EXPERIMENTAL

Therapeutic Education and Nursing Support Program for Supportive Care. In addition to conventional gynecological follow-up care, patients will participate in an initial educational assessment day. During this day, the patient will have a discussion with the pivot nurse to define personalized objectives, which will guide the choice of workshops and supportive care in the outpatient educational program.

Other: Supportive Care

Control group

NO INTERVENTION

Patients follow conventional care.

Interventions

Initial Educational Assessment In addition to standard care, patients will meet the coordinating nurse for an initial educational assessment to evaluate their needs and present the multidisciplinary workshop program and individual support options. The nurse will register the patient for the first session, provide program materials, schedule the first follow-up call (1 month post-inclusion), and collect study questionnaires and demographics. If needed, the assessment may be scheduled within 15 days of inclusion. Educational Workshops Patients may attend workshops on topics like endometriosis, diet, sexuality, pain, fatigue, emotions, Pilates, non-drug symptom management, hypnoanalgesia, and fertility. At least three workshops are required, offered over two days. Telephone Follow-up Monthly calls for 6 months, then at 9 and 12 months, will monitor symptoms and refer patients to support services as needed.

The experimental group will participate in a therapeutic education and nursing support

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signed informed consent,
  • Age ≥ 18 years,
  • Patient diagnosed with endometriosis confirmed by pelvic ultrasound and/or MRI,
  • Patient experiencing chronic pelvic-perineal pain (± dysmenorrhea, dyspareunia, etc.) for at least 3 months,
  • Ability to read and understand French,
  • Affiliation with a social security system or equivalent.

You may not qualify if:

  • Patient having already participated in an educational program or received multidisciplinary follow-up (involving at least 3 different healthcare professionals simultaneously within the same facility) in the past 12 months,
  • Patient in an emergency situation, or under legal protection measures (guardianship, curatorship, or judicial protection) and unable to give consent,
  • For patients at the experimental center only: inability to comply with study follow-up due to geographical, social, or psychological reasons.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Clinique Axium

Aix-en-Provence, 13100, France

RECRUITING

Centre Hospitalier Emile Roux

Le Puy-en-Velay, 43000, France

NOT YET RECRUITING

MeSH Terms

Conditions

Endometriosis

Interventions

Palliative Care

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

Patient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and Services

Central Study Contacts

Emilie Gadéa, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 7, 2025

First Posted

August 21, 2025

Study Start

December 17, 2025

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2029

Last Updated

December 22, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

The study sponsor is the owner of the data and no use or transmission to a third party may be made without its prior consent. All information resulting from this clinical research protocol is considered confidential.

Locations